Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats

Journal of Hypertension

Volumn 24, Issue 8, 2006, Pages 1607-1617

  Muñoz, Marina C ^a   Argentino, Danila P ^a   Dominici, Fernando P ^a   Turyn, Daniel ^a   Toblli, Jorge E ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

Author keywords

Angiotensin antagonist; Angiotensin II; Insulin resistance; Liver; Signal transduction

Indexed keywords

ANGIOTENSIN II; ANTIBODY; INSULIN RECEPTOR; IRBESARTAN; OIL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; SERINE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; LIPID STORAGE; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; SIGNAL TRANSDUCTION;

EID: 33746699630     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000239297.63377.3f     Document Type: Article

References (52)

1. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocrine Rev 1995; 16:117-142.
2. LeRoith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001; 24:588-597.
3. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799-806.
4. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-481.
5. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-381.
6. Higashiura K, Ura N, Takada T, Li Y, Torii T, Togashi N, et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000; 13:290-297.
7. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38:884-890.
8. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43:1003-1110.
9. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-473.
10. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27:1015.
11. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6:87-97.
12. Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 2001; 11:437-441. Erratum in: Trends Cell Biol 2002; 12:56.
13. Johnston AM, Pirola L, Van Obberghen E. Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett 2003; 546:32-36.
14. Clément S, Krause U, Desmedt F, Tanti J-F, Behrends J, Pesesse X, et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 2001; 409:92-97.
15. Coba MP, Muñoz MC, Dominici FP, Toblli JE, Peña C, Bartke A, Turyn D. Increased in vivo phosphorylation of insulin receptor at serine 994 in the liver of obese insulin-resistant Zucker rats. J Endocrinol 2004; 182:433-444.
16. O'Donnell MP, Cray GS, Oda H, Kasiske BL, Powell JR, Keane WF. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int Suppl 1997; 63:S218-S220.
17. Dohi Y, Criscione L, Pfeiffer K, Luscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994; 24:372-379.
18. Toblli JE, DeRosa G, Cao G, Piorno P, Pagano P. ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats. Kidney Int 2004; 65:2343-2359.
19. Mezzano SA, Aros CA, Droguett A, Burgos ME, Ardiles LG, Flores CA, et al. Renal angiotensin II up-regulation and myofibroblast activation in human membranes nephropathy. Kidney Int 2003; 64 (Suppl. 86):539-545.
20. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577-580.
21. Coba MP, Turyn D, Peña C. Synthesis and immunogenic properties of phosphopeptides related to the human insulin receptor. J Pept Res 2003; 61:17-23.
22. Argentino DP, Dominici FP, Munoz MC, Al-Regaiey K, Bartke A, Turyn D. Effects of long-term caloric restriction on glucose homeostasis and on the first steps of the insulin signaling system in skeletal muscle of normal and Ames dwarf (Prop1df/Prop1df) mice. Exp Gerontol 2005; 40:27-35.
23. Anai M, Funaki M, Ogihara T, Terasaki J, Inukai K, Katagiri H, et al. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 1998; 47:13-23.
24. Nawano M, Ueta K, Oku A, Arakawa K, Saito A, Funaki M, et al. Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver. Biochem Biophys Res Commun 1999; 266:252-256.
25. Kim YB, Peroni OD, Franke TF, Kahn BB. Divergent regulation of Akt1 and Akt2 isoforms in insulin target tissues of obese Zucker rats. Diabetes 2000; 49:847-856.
26. Paez-Espinosa V, Carvalho CR, Alvarez-Rojas F, Janeri L, Velloso LA, Boschero AC, Saad MJ. Insulin induces tyrosine phosphorylation of Shc and stimulates Shc/GRB2 association in insulin-sensitive tissues of the intact rat. Endocrine 1998; 2:193-200.
27. Dominici FP, Arostegui Diaz G, Bartke A, Kopchick JJ, Turyn D. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. J Endocrinol 2000; 166:579-590.
28. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93:12490-12495.
29. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100:2158-2169.
30. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999; 107:133-139.
31. Xiao HD, Fuchs S, Frenzel K, Teng L, Bernstein KE. Circulating versus local angiotensin II in blood pressure control: lessons from tissue-specific expression of angiotensin-converting enzyme (ACE). Crit Rev Eukaryot Gene Expr 2004; 14:137-145.
32. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287:227-232.
33. Saad MJA, Araki E, Miralpeix M, Rothemberg PL, White MF, Kahn CR. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 1992; 90:1839-1849.
34. Saad MJ, Folli F, Kahn CR. Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells. Endocrinology 1995; 136:1579-1588.
35. Kerouz NJ, Horsch D, Pons S, Kahn CR. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 1997; 100:3164-3172.
36. Qiao LY, Zhande R, Jetton TL, Zhou G, Sun XJ. In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem 2002; 277:26530-26539.
37. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factortreated cells through targeting multiple serine kinases. J Biol Chem 2003; 278:24944-24950.
38. Avignon A, Yamada K, Zhou X, Spencer B, Cardona O, Saba-Siddique S, et al. Chronic activation of protein kinase C in soleus muscles and other tissues of insulin-resistant type II diabetic Goto-Kakizaki (GK), obese/aged, and obese/Zucker rats. A mechanism for inhibiting glycogen synthesis. Diabetes 1996; 45:1396-1404.
39. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C and alterations of the insulin signaling cascade. Diabetes 1999; 48:1274-1279.
40. Cortright R, Azevedo JL Jr, Zhou Q, Sinha M, Pories WJ, Itani SI, Dohm GL. Protein kinase C modulates insulin action in human skeletal muscle. Am J Physiol Endocrinol Metab 2000; 278:E553-E562.
41. Donnelly R, Reed MJ, Azhar S, Reaven GM. Expression of the major isoenzyme of protein kinase C in skeletal muscle, nPKC theta, varies with muscle type and in response to fructose-induced insulin resistance. Endocrinology 1994; 135:2369-2374.
42. Nawano M, Anai M, Funaki M, Kobayashi H, Kanda A, Fukushima Y, et al. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 1999; 48:1248-1255.
43. Laine H, Yki-Jarvinen H, Kirvela O, Tolvanen T, Raitakari M, Solin O, et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 1998; 101:1156-1162.
44. Dal Ponte DB, Fogt DL, Jacob S, Henriksen EJ. Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. Metabolism 1998; 47:982-987.
45. Toblli JE, Cao G, DeRosa G, Piorno P, Pagano P. ACE inhibition ameliorates cardiac steatosis in obese Zucker rats [Abstract]. Am J Hypertens 2004; 17:219.
46. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40:872-879.
47. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46:137-143.
48. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104:447-457.
49. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105:311-320.
50. Carvalheira JB, Calegari VC, Zecchin HG, Nadruz W Jr, Guimaraes RB, Ribeiro EB, et al. The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology 2003; 144:5604-5614.
51. Bard-Chapeau EA, Hevener AL, Long S, Zhang EE, Olefsky JM, Feng GS. Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. Nat Med 2005; 11:567-571.
52. Izawa Y, Yoshizumi M, Fujita Y, Ali N, Kanematsu Y, Ishizawa K, et al. ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp Cell Res 2005; 308:291-299.